1. Antiviral Effect of Microalgae Phaeodactylum tricornutum Protein Hydrolysates against Dengue Virus Serotype 2.
- Author
-
Rivera-Serrano, Bianca Vianey, Cabanillas-Salcido, Sandy Lucero, Cordero-Rivera, Carlos Daniel, Jiménez-Camacho, Ricardo, Norzagaray-Valenzuela, Claudia Desiree, Calderón-Zamora, Loranda, De Jesús-González, Luis Adrián, Reyes-Ruiz, José Manuel, Farfan-Morales, Carlos Noe, Romero-Utrilla, Alejandra, Ruíz-Ruelas, Víctor Manuel, Camberos-Barraza, Josué, Camacho-Zamora, Alejandro, De la Herrán-Arita, Alberto Kousuke, Angulo-Rojo, Carla, Guadrón-Llanos, Alma Marlene, Rábago-Monzón, Ángel Radamés, Perales-Sánchez, Janitzio Xiomara Korina, Valdez-Flores, Marco Antonio, and Del Ángel, Rosa María
- Abstract
Dengue, caused by the dengue virus (DENV), is a global health threat transmitted by Aedes mosquitoes, resulting in 400 million cases annually. The disease ranges from mild to severe, with potential progression to hemorrhagic dengue. Current research is focused on natural antivirals due to challenges in vector control. This study evaluates the antiviral potential of peptides derived from the microalgae Phaeodactylum tricornutum, known for its bioactive compounds. Microalgae were cultivated under controlled conditions, followed by protein extraction and hydrolysis to produce four peptide fractions. These fractions were assessed for cytotoxicity via the MTT assay and antiviral activity against DENV serotype 2 using flow cytometry and plaque formation assays. The 10–30 kDa peptide fraction, at 150 and 300 μg/mL concentrations, demonstrated no cytotoxicity and significantly reduced the percentage of infected cells and viral titers. These findings suggest that peptides derived from Phaeodactylum tricornutum exhibit promising antiviral activity against dengue virus serotype 2, potentially contributing to developing new therapeutic approaches for dengue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF